In the clinic, the diagnostic for solid tumors is based on histopathological data including tumor differentiation and on the evaluation of serum markers, such as carcinoembryonic antigen (CEA), prostate serum antigen (PSA), and other circulant markers [306,307,308,309]. This evidence concerns the gene CEACAM5 and neoplasm.